On our screens:Stocks with no debt
The financials
Caris Life Sciences, Inc. by the numbers
Caris Life Sciences, Inc. (CAI) reported revenue of $264M in Q2 2026 (quarter ended Jun 30, 2026), up 45% from the same quarter a year earlier. That came with net loss of $637K. For the full year FY2025, revenue was $812M (+97% year on year) and net income −$68M. Its largest product in Q2 2026 was Molecular Profiling Services at $252M, 96% of the disclosed total, well ahead of Pharma Research And Development Services at 4.3%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $264M | $181M | +45% |
| Operating income | $27M | −$18M | to a profit |
| Net income | −$637K | −$72M | n/a |
| Diluted EPS | $0.00 | −$7.97 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Molecular Profiling Services | $252M | 96% |
| Pharma Research And Development Services | $11M | 4.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $263.7M (+22%)
Molecular Profiling Services grew +55% year on yearPharma Research And Development Services -38% year on year
Segment Latestquarter on quarteryear on year
- Molecular Profiling Services$252.3M$252.3MQoQ +20%year on year +55%+20%+55%
- Pharma Research And Development Services$11.5M$11.5MQoQ +113%year on year -38%+113%-38%